Transient Lactic Acidosis and Elevation of Transaminases after the Introduction of Remdesivir in a Patient with Acute Kidney Injury.


Journal

Case reports in critical care
ISSN: 2090-6420
Titre abrégé: Case Rep Crit Care
Pays: United States
ID NLM: 101598416

Informations de publication

Date de publication:
2024
Historique:
received: 14 08 2023
revised: 25 01 2024
accepted: 13 02 2024
medline: 4 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: epublish

Résumé

A 56-year-old woman was transferred to the intensive care unit (ICU) two days after an allogeneic stem cell transplantation (ASCT) when she presented acute respiratory distress due to the relapse of a SARS-CoV-2 infection. Following that, she received two intravenous doses of 100 mg remdesivir. Subsequently, the patient developed multiple instances of diarrhea, progressing to oliguria and acute kidney injury, necessitating continuous venovenous hemofiltration (CVVH). Despite the absence of signs of hypoxemia or cardiocirculatory failure requiring vasopressor intervention, a progressive lactic acidosis emerged. Two days after the onset of lactic acidosis, a significant rise in aminotransferases and lactate dehydrogenase occurred, in the absence of encephalopathy and coagulation disorders. Remdesivir therapy had been interrupted upon the initial signs of lactic acidosis. Despite an improvement in liver function tests and lactic acidosis, the patient's condition deteriorated, ultimately leading to her demise on day 29 due to newly arising hematological complications.

Identifiants

pubmed: 38435396
doi: 10.1155/2024/6631866
pmc: PMC10904205
doi:

Types de publication

Case Reports

Langues

eng

Pagination

6631866

Informations de copyright

Copyright © 2024 Elise André et al.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

Elise André (E)

Department of Intensive Care, Cliniques Saint-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium.

Florian Lemaitre (F)

Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, Environnement et travail)-UMR_S 1085, Rennes, France.
FHU SUPORT, Rennes F-35000, France.

Marie-Clémence Verdier (MC)

Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, Environnement et travail)-UMR_S 1085, Rennes, France.
FHU SUPORT, Rennes F-35000, France.

Vincent Haufroid (V)

Clinical Chemistry Department, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium.
Louvain Centre for Toxicology and Applied Pharmacology, UCLouvain, 1200 Brussels, Belgium.

João Pinto Pereira (JP)

Department of Intensive Care, Cliniques Saint-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium.

Philippe Hantson (P)

Department of Intensive Care, Cliniques Saint-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium.
Louvain Centre for Toxicology and Applied Pharmacology, UCLouvain, 1200 Brussels, Belgium.

Classifications MeSH